Group A streptococcal necrotizing fasciitis: reducing the risk of unwarranted litigation
Zuber D. Mulla, MSPH, PhD
Division of Epidemiology, School of Public Health, University of Texas Health Science Center at Houston, El Paso, TX 79902, USA
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect.
Invasive group A streptococcal (GAS) disease is a disease of public health importance in the United States. The annual incidence of invasive GAS disease is 4 times that of meningococcal disease [1]. The case-fatality rates of GAS necrotizing fasciitis (NF) and streptococcal toxic shock syndrome, 2 severe manifestations of invasive GAS disease, are high (20% and 45%, respectively).
To access this article, please choose from the options below
Purchase access to this article
Claim Access
If you are a current subscriber with Society Membership or an Account Number, claim your access now.
Subscribe to this title
Purchase a subscription to gain access to this and all other articles in this journal.
Institutional Access
Visit ScienceDirect to see if you have access via your institution.
© 2005 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
Access this article on
Visit ScienceDirect to see if you have access via your institution.
Article Tools
Related Articles
Searching for related articles..
